id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2016-E-2181-0005,FDA,FDA-2016-E-2181,"Determination of Regulatory Review Period for Purposes of Patent
Extension; XURIDEN",Notice,Determinations,2017-11-29T05:00:00Z,2017,11,2017-11-29T05:00:00Z,2018-01-30T04:59:59Z,2017-11-29T16:32:21Z,2017-25770,0,0,0900006482cbbcc8
FDA-2016-E-2181-0004,FDA,FDA-2016-E-2181,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2017-08-21T04:00:00Z,2017,8,2017-08-21T04:00:00Z,,2017-08-21T16:42:47Z,,0,0,0900006482a8c9ca